Quick Answer
OKYO Pharma Ltd reported R&D Expense of $2.25 million for fiscal year 2025.
OKYO Pharma Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.25M | -72.7% |
| 2024 | $8.24M | +30.1% |
| 2023 | $6.34M | +293.8% |
| 2022 | $1.61M | +362.1% |
| 2021 | $348.3K | -32.8% |
| 2020 | $518.1K | — |
- OKYO Pharma Ltd showed a decrease of -72.7% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, OKYO Pharma Ltd’s r&d expense has grown by 335.1% (from $518.1 thousand to $2.25 million).
- The most recent figure is from OKYO Pharma Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 18, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: